Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: GlobeNewswire
MarketNewsUpdates News Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased consumer focus on preventive and longevity-focused health. A report from Grand View Research said that the U.S. anti-aging products market size was USD 14.05 billion in 2024 and is projected to reach USD 27.44 billion by 2033, growing at a CAGR of 8.0% from 2025 to 2033. Globally, the anti-aging market is forecasted to surpass $421.4 billion in revenue by 2030 with a compound annual growth rate of 8.1%, per data from a report by P&S Intelligence. The market is driven by an increasing demand for high-performance skincare solutions that offer visible, long-term results. Consumers are particularly focused on products that target fine lines, wrinkles, and skin elasticity, with a growing interest in advanced formulations that combine anti-aging benefits with overall skin health. The Grand View Resear
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Lightning Round: Recursion Pharmaceuticals and NuScale Power [CNBC]CNBC
- Cramer's Lightning Round: Recursion Pharmaceuticals ‘has been horrendous' [CNBC]CNBC
- Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025GlobeNewswire
- Is Recursion Pharmaceuticals a Meme Stock? [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader? [Seeking Alpha]Seeking Alpha
RXRX
Earnings
- 11/5/25 - Beat
RXRX
Sec Filings
- 12/4/25 - Form 4
- 12/4/25 - Form 144
- 12/2/25 - Form 144
- RXRX's page on the SEC website